ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2016
Durable Viral Suppression and Transmission Risk Potential Among Persons With Diagnosed HIV Infection: United States, 2012-2013.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 77 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
77 citing papers in PubMed, 1 synthesis or guideline pooled it, 126 citations in OpenAlex.
- Guideline
- Trial
- Positive Health Check evaluation: A type 1 hybrid design randomized trial to decrease HIV viral loads in patients seen in HIV primary care.Contemporary clinical trials · 2020Trial
- Effects of incentivizing viral suppression in previously incarcerated adults living with HIV.HIV research & clinical practice · 2020Trial
- Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial.Journal of acquired immune deficiency syndromes (1999) · 2019Trial
- Financial Incentives for Linkage to Care and Viral Suppression Among HIV-Positive Patients: A Randomized Clinical Trial (HPTN 065).JAMA internal medicine · 2017Trial
- A US-Based National Virtual Cohort of People Living With HIV at Risk for Viral Nonsuppression: Protocol for the EPI-LoVE Prospective Cohort Study.JMIR research protocols · 2026Article
- Sustained viral suppression among people with HIV in the era of Undetectable = Untransmittable (U = U) in Australia.AIDS (London, England) · 2026Article
- Diminished social support as an explanatory mechanism in the relationship between stigma and engagement HIV care.Journal of behavioral medicine · 2025Article
- Predictors of sustained human immunodeficiency virus viral-load suppression before and after the adoption of Treat All policy in Rwanda.World journal of virology · 2025Article
- Depressive symptoms among women of reproductive age with and without HIV in the Southern United States.AIDS (London, England) · 2025Observational
- The effect of antidepressant treatment on viral suppression among people with HIV diagnosed with depression in an urban clinic.AIDS (London, England) · 2025Observational
- Antiretroviral Therapy Use and Disparities Among Medicare Beneficiaries with HIV.Journal of general internal medicine · 2024Observational
- Changing how the third 95 is counted: suitable indicators for measuring U = U with findings from Taiwan.AIDS research and therapy · 2024Article
- Low Uptake of Long-Acting Injectables in the First 2.5 Years Following Approval Among a Cohort of People Living With HIV.Open forum infectious diseases · 2024Article
- Article
- Article
- Client preferences for HIV Care Coordination Program features in New York City: latent class analysis of a discrete choice experiment.Journal of the International AIDS Society · 2023Article
- Prioritization of Evidence-Based and Evidence-Informed Interventions for Retention in Medical Care for Persons with HIV.AIDS and behavior · 2023Review
- Evaluating surveillance definitions of HIV viral suppression 2015-2019: Which definition best detected barriers to care?Journal of public health research · 2023Article
17 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
Abstract
backgroundWe examined durable viral suppression, cumulative viral load (VL) burden, and transmission risk potential among human immunodeficiency virus (HIV)-diagnosed persons in care.
methodsUsing data from the National HIV Surveillance System from 17 jurisdictions with complete reporting of VL test results, we determined the percentage of persons in HIV care who achieved durable viral suppression (all VL results <200 copies/mL) and examined viremia copy-years and time spent above VL levels that increase the risk of HIV transmission during 2012-2013.
resultsOf 265 264 persons in HIV care in 2011, 238 641 had at least 2 VLs in 2012-2013. The median number of VLs per individual during the 2-year period was 5. Approximately 62% had durable viral suppression. The remaining 38% had high VL burden (geometric mean of viremia copy-years, 7261) and spent an average of 438 days, 316 days, and 215 days (60%, 43.2%, and 29.5% of the 2-year period) above 200, 1500, and 10 000 copies/mL. Women, blacks/African Americans, Hispanics/Latinos, persons with HIV infection attributed to transmission other than male-to-male sexual contact, younger age groups, and persons with gaps in care had higher viral burden and transmission risk potential.
conclusionsTwo-thirds of persons in HIV care had durable viral suppression during a 2-year period. One-third had high VL burden and spent substantial time above VL levels with increased risk of onward transmission. More intervention efforts are needed to improve retention in care and medication adherence so that more persons in HIV care achieve durable viral suppression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.